BAQSIMI

Drug Lilly USA, LLC
Total Payments
$1.2M
Transactions
34,871
Doctors
9,033
Companies
4

Payment Trends by Year

Year Amount Transactions Doctors
2024 $7,409 253 194
2023 $97,283 5,544 2,667
2022 $151,757 8,997 4,036
2021 $397,688 9,938 4,178
2020 $388,836 6,032 2,279
2019 $192,436 4,107 1,843

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $646,850 728 52.4%
Food and Beverage $569,077 33,999 46.1%
Consulting Fee $13,425 11 1.1%
Travel and Lodging $6,057 133 0.5%

Top Doctors Receiving Payments for BAQSIMI — Page 362

Doctor Specialty Location Total Records
, MD Internal Medicine Corpus Christi, TX $3.33 1
, NP Family Corpus Christi, TX $3.33 1
Kacy Ramirez Family Corpus Christi, TX $3.33 1
, M.D Endocrinology, Diabetes & Metabolism Port Saint Lucie, FL $3.24 1
, DO Family Medicine Woodville, OH $2.59 1
, NP Adult Health Naples, FL $2.52 1
, M.D Endocrinology, Diabetes & Metabolism Cape Coral, FL $2.51 1
, MD Family Medicine Virginia Beach, VA $1.63 1
, M.D Neurology Las Vegas, NV $1.15 1

About BAQSIMI

BAQSIMI is a drug associated with $1.2M in payments to 9,033 healthcare providers, recorded across 34,871 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.

Payment data is available from 2019 to 2024. In 2024, $7,409 was paid across 253 transactions to 194 doctors.

The most common payment nature for BAQSIMI is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($646,850, 52.4% of total).